TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02393365

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HCV serology
Description: In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation.
Study: NCT01970436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Prenatal Care
Description: Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
Study: NCT03442296

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study: NCT01266811

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo, Velcade and dexamethasone
Description: Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab, Velcade and dexamethasone
Description: Given in 21-day treatment cycles
Study: NCT01018069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEG35156
Description: 2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: AEG35156
Description: 2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
Study: NCT01969604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Lifestyle Counselling
Description: The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand.
Study: NCT02201199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine U200 HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine U500 HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine U100 HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT02993640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin + nitro
Description: vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
Study: NCT00959192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QS-21
Description: IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QS-21
Description: IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
Study: NCT01724164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic assisted therapy
Description: This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Robotic Rehabilitation with PI
Description: The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation with FES
Description: This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
Study: NCT00171964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid in combination with therapy
Study: NCT00101790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pamidronate
Description: There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
Study: NCT03561220

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care IMRT (Photon)
Description: As this trial is pragmatic, all treatment will be standard of care.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Proton Therapy
Description: As this trial is pragmatic, all treatment will be standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Arm 1: Standard Proton Therapy
Description: 78.0 Gy (RBE) in 39 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Arm 2: Hypofractionated Proton Therapy
Description: 60.0 Gy (RBE) in 20 fractions
Study: NCT03364114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoRotor Mucosal Resection System
Description: The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continued Ablation
Description: Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
Study: NCT01029691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: Women will use positive airway pressure until delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: Women will use positive airway pressure until delivery
Study: NCT02672982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTPSY treatment
Description: The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NUT treatment
Description: Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
Study: NCT01203228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myeloablative conditioning
Description: Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW
Study: NCT01523886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
Study: NCT00661362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Oral tablet, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: oral tablet, once daily for 24 weeks
Study: NCT00679354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00775138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 280 mg Arikayce™
Description: Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Cohort 1
Description: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 560 mg Arikayce™
Description: Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT01523886

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: Intravenous use: 0,3 mg/kg followed by NaCl-infusion
Study: NCT01746927

Intervention type: OTHER
Intervention: Glidescope Cricoid pressure
Description: The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
Study: NCT02758327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraTears Lubricating Eye Drops
Description: Sodium Carboxy-methylcellulose 0.25% eye Lubricant
Study: NCT01673035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT, exposure and response prevention
Description: This intervention entails different exercises aimed exposure to health anxiety stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BSM, stress management and applied relaxation
Description: BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
Study: NCT04733365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERIC protocol
Description: ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
Study: NCT03849742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive Uber rides
Study: NCT01038024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 tablet composed of antioxidants and minerals
Description: 1 tablet daily
Study: NCT03041246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor fascial mobilization
Description: The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
Study: NCT03309358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled SNSP113
Description: A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
Study: NCT00775138

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Cohort 2
Description: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT03869931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 100 mg or 300 mg (according to CrCl)
Study: NCT03969589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning-Mental Health (RLP-MH) Intervention
Description: RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.

Intervention type: OTHER
Group type: OTHER
Intervention: Written Materials on Reproductive Life Planning
Description: Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
Study: NCT02194634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Sham intravitreal injection at first month, then repeated as needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser treatment at first month, then repeated as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham laser
Description: Sham laser at first month, then repeated as needed.
Study: NCT03446664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microburst Stimulation
Description: Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
Study: NCT02797496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric Motor Strengthening
Description: In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
Study: NCT03674879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Patient contact attempted with text message.
Study: NCT00498888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: Detrusitol SR 4 mg, 1 capsule for a day, 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder training
Description: Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor rehabilitation
Description: The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
Study: NCT01028131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention (5As)
Description: After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention (5As)
Description: After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
Study: NCT02305498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous yoga practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restorative (gentle) yoga practice
Study: NCT00512902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Up to 600 mg QD PO for up to 1 year.
Study: NCT02782026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Olfactory Signature (Artificial Nose)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Olfactory Signature (Artificial Nose)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Olfactory Signature (Artificial Nose)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Olfactory Signature (Artificial Nose)
Study: NCT04847180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
Study: NCT01890863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate / Salmeterol Xinafoate DISKUS
Description: Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate / Salmeterol Xinafoate DISKUS
Description: Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate / Salmeterol Xinafoate ROTACAP
Description: Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate / Salmeterol Xinafoate ROTACAP
Description: Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
Study: NCT00699998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Commercially-available Aspirin
Description: Low-dose aspirin, oral, as prescribed by physician through end of study